Logo image of ZEG.DE

ASTRAZENECA PLC (ZEG.DE) Stock Fundamental Analysis

FRA:ZEG - Deutsche Boerse Ag - GB0009895292 - Common Stock - Currency: EUR

119.1  -1.2 (-1%)

Fundamental Rating

5

ZEG gets a fundamental rating of 5 out of 10. The analysis compared the fundamentals against 52 industry peers in the Pharmaceuticals industry. ZEG has an excellent profitability rating, but there are some minor concerns on its financial health. ZEG has a correct valuation and a medium growth rate.


Dividend Valuation Growth Profitability Health

8

1. Profitability

1.1 Basic Checks

In the past year ZEG was profitable.
ZEG had a positive operating cash flow in the past year.
ZEG had positive earnings in each of the past 5 years.
In the past 5 years ZEG always reported a positive cash flow from operatings.
ZEG.DE Yearly Net Income VS EBIT VS OCF VS FCFZEG.DE Yearly Net Income VS EBIT VS OCF VS FCFYearly Net Income VS EBIT VS OCF VS FCF 2015 2016 2017 2018 2019 2020 2021 2022 2023 2024 2B 4B 6B 8B 10B

1.2 Ratios

The Return On Assets of ZEG (7.31%) is better than 61.54% of its industry peers.
ZEG's Return On Equity of 18.94% is fine compared to the rest of the industry. ZEG outperforms 69.23% of its industry peers.
ZEG's Return On Invested Capital of 14.10% is amongst the best of the industry. ZEG outperforms 80.77% of its industry peers.
Measured over the past 3 years, the Average Return On Invested Capital for ZEG is below the industry average of 14.50%.
The 3 year average ROIC (11.62%) for ZEG is below the current ROIC(14.10%), indicating increased profibility in the last year.
Industry RankSector Rank
ROA 7.31%
ROE 18.94%
ROIC 14.1%
ROA(3y)5.35%
ROA(5y)4.19%
ROE(3y)13.78%
ROE(5y)12.42%
ROIC(3y)11.62%
ROIC(5y)9.52%
ZEG.DE Yearly ROA, ROE, ROICZEG.DE Yearly ROA, ROE, ROICYearly ROA, ROE, ROIC 2015 2016 2017 2018 2019 2020 2021 2022 2023 2024 5 10 15 20

1.3 Margins

The Profit Margin of ZEG (14.14%) is better than 65.38% of its industry peers.
ZEG's Profit Margin has improved in the last couple of years.
ZEG has a better Operating Margin (24.05%) than 67.31% of its industry peers.
ZEG's Operating Margin has improved in the last couple of years.
The Gross Margin of ZEG (82.36%) is better than 82.69% of its industry peers.
In the last couple of years the Gross Margin of ZEG has remained more or less at the same level.
Industry RankSector Rank
OM 24.05%
PM (TTM) 14.14%
GM 82.36%
OM growth 3Y21.43%
OM growth 5Y8.6%
PM growth 3Y251.6%
PM growth 5Y18.9%
GM growth 3Y3.31%
GM growth 5Y0.47%
ZEG.DE Yearly Profit, Operating, Gross MarginsZEG.DE Yearly Profit, Operating, Gross MarginsYearly Profit, Operating, Gross Margins 2015 2016 2017 2018 2019 2020 2021 2022 2023 2024 20 40 60 80

4

2. Health

2.1 Basic Checks

ZEG has a Return on Invested Capital (ROIC), which is just above the Cost of Capital (WACC), which means it is creating some value.
Compared to 1 year ago, ZEG has about the same amount of shares outstanding.
Compared to 5 years ago, ZEG has more shares outstanding
The debt/assets ratio for ZEG is higher compared to a year ago.
ZEG.DE Yearly Shares OutstandingZEG.DE Yearly Shares OutstandingYearly Shares Outstanding 2015 2016 2017 2018 2019 2020 2021 2022 2023 2024 500M 1B 1.5B
ZEG.DE Yearly Total Debt VS Total AssetsZEG.DE Yearly Total Debt VS Total AssetsYearly Total Debt VS Total Assets 2015 2016 2017 2018 2019 2020 2021 2022 2023 2024 20B 40B 60B 80B 100B

2.2 Solvency

ZEG has an Altman-Z score of 4.95. This indicates that ZEG is financially healthy and has little risk of bankruptcy at the moment.
ZEG has a better Altman-Z score (4.95) than 80.77% of its industry peers.
ZEG has a debt to FCF ratio of 3.46. This is a good value and a sign of high solvency as ZEG would need 3.46 years to pay back of all of its debts.
ZEG's Debt to FCF ratio of 3.46 is fine compared to the rest of the industry. ZEG outperforms 61.54% of its industry peers.
A Debt/Equity ratio of 0.71 indicates that ZEG is somewhat dependend on debt financing.
The Debt to Equity ratio of ZEG (0.71) is comparable to the rest of the industry.
Industry RankSector Rank
Debt/Equity 0.71
Debt/FCF 3.46
Altman-Z 4.95
ROIC/WACC1.6
WACC8.83%
ZEG.DE Yearly LT Debt VS Equity VS FCFZEG.DE Yearly LT Debt VS Equity VS FCFYearly LT Debt VS Equity VS FCF 2015 2016 2017 2018 2019 2020 2021 2022 2023 2024 10B 20B 30B 40B

2.3 Liquidity

A Current Ratio of 0.90 indicates that ZEG may have some problems paying its short term obligations.
The Current ratio of ZEG (0.90) is worse than 76.92% of its industry peers.
ZEG has a Quick Ratio of 0.90. This is a bad value and indicates that ZEG is not financially healthy enough and could expect problems in meeting its short term obligations.
ZEG has a Quick ratio of 0.70. This is in the lower half of the industry: ZEG underperforms 73.08% of its industry peers.
Industry RankSector Rank
Current Ratio 0.9
Quick Ratio 0.7
ZEG.DE Yearly Current Assets VS Current LiabilitesZEG.DE Yearly Current Assets VS Current LiabilitesYearly Current Assets VS Current Liabilites 2015 2016 2017 2018 2019 2020 2021 2022 2023 2024 10B 20B 30B

5

3. Growth

3.1 Past

ZEG shows a strong growth in Earnings Per Share. In the last year, the EPS has been growing by 16.91%, which is quite good.
ZEG shows quite a strong growth in Earnings Per Share. Measured over the last years, the EPS has been growing by 18.59% yearly.
Looking at the last year, ZEG shows a quite strong growth in Revenue. The Revenue has grown by 15.48% in the last year.
ZEG shows quite a strong growth in Revenue. Measured over the last years, the Revenue has been growing by 17.27% yearly.
EPS 1Y (TTM)16.91%
EPS 3Y15.85%
EPS 5Y18.59%
EPS Q2Q%20.87%
Revenue 1Y (TTM)15.48%
Revenue growth 3Y13.06%
Revenue growth 5Y17.27%
Sales Q2Q%7.17%

3.2 Future

The Earnings Per Share is expected to grow by 11.35% on average over the next years. This is quite good.
The Revenue is expected to grow by 6.34% on average over the next years.
EPS Next Y12.48%
EPS Next 2Y12.94%
EPS Next 3Y11.87%
EPS Next 5Y11.35%
Revenue Next Year8.37%
Revenue Next 2Y7.23%
Revenue Next 3Y6.74%
Revenue Next 5Y6.34%

3.3 Evolution

The estimated forward EPS growth is still strong, although it is decreasing when compared to the stronger growth in the past years.
When comparing the Revenue growth rate of the last years to the growth rate of the upcoming years, we see that the growth is decreasing.
ZEG.DE Yearly Revenue VS EstimatesZEG.DE Yearly Revenue VS EstimatesYearly Revenue VS Estimates 2014 2016 2018 2020 2022 2024 2026 2028 2030 2032 20B 40B 60B 80B
ZEG.DE Yearly EPS VS EstimatesZEG.DE Yearly EPS VS EstimatesYearly EPS VS Estimates 2014 2016 2018 2020 2022 2024 2026 2028 2030 2032 5 10 15

4

4. Valuation

4.1 Price/Earnings Ratio

With a Price/Earnings ratio of 16.16, ZEG is valued correctly.
ZEG's Price/Earnings ratio is in line with the industry average.
ZEG is valuated rather cheaply when we compare the Price/Earnings ratio to 27.29, which is the current average of the S&P500 Index.
A Price/Forward Earnings ratio of 13.34 indicates a correct valuation of ZEG.
Compared to the rest of the industry, the Price/Forward Earnings ratio of ZEG indicates a somewhat cheap valuation: ZEG is cheaper than 63.46% of the companies listed in the same industry.
ZEG is valuated rather cheaply when we compare the Price/Forward Earnings ratio to 21.74, which is the current average of the S&P500 Index.
Industry RankSector Rank
PE 16.16
Fwd PE 13.34
ZEG.DE Price Earnings VS Forward Price EarningsZEG.DE Price Earnings VS Forward Price Earnings ChartPrice Earnings - Forward Price Earnings PE FPE 20 40 60 80

4.2 Price Multiples

Compared to the rest of the industry, the Enterprise Value to EBITDA ratio of ZEG indicates a slightly more expensive valuation: ZEG is more expensive than 67.31% of the companies listed in the same industry.
ZEG's Price/Free Cash Flow is on the same level as the industry average.
Industry RankSector Rank
P/FCF 47.39
EV/EBITDA 22.95
ZEG.DE Per share dataZEG.DE EPS, Sales, OCF, FCF, BookValue per sharePer Share Data Per Share 0 5 10 15

4.3 Compensation for Growth

ZEG's PEG Ratio(NY), which compensates the Price/Earnings for growth, indicates a correct valuation of the company.
ZEG has an outstanding profitability rating, which may justify a higher PE ratio.
PEG (NY)1.29
PEG (5Y)0.87
EPS Next 2Y12.94%
EPS Next 3Y11.87%

4

5. Dividend

5.1 Amount

ZEG has a Yearly Dividend Yield of 2.41%. Purely for dividend investing, there may be better candidates out there.
ZEG's Dividend Yield is a higher than the industry average which is at 3.05.
Compared to an average S&P500 Dividend Yield of 2.37, ZEG has a dividend comparable with the average S&P500 company.
Industry RankSector Rank
Dividend Yield 2.41%

5.2 History

The dividend of ZEG has a limited annual growth rate of 1.40%.
Dividend Growth(5Y)1.4%
Div Incr Years0
Div Non Decr Years0

5.3 Sustainability

63.60% of the earnings are spent on dividend by ZEG. This is not a sustainable payout ratio.
ZEG's earnings are growing more than its dividend. This makes the dividend growth sustainable.
DP63.6%
EPS Next 2Y12.94%
EPS Next 3Y11.87%
ZEG.DE Yearly Income VS Free CF VS DividendZEG.DE Yearly Income VS Free CF VS DividendYearly Income VS Free CF VS Dividend 2015 2016 2017 2018 2019 2020 2021 2022 2023 2024 2B 4B 6B
ZEG.DE Dividend Payout.ZEG.DE Dividend Payout, showing the Payout Ratio.ZEG.DE Dividend Payout.PayoutRetained Earnings

ASTRAZENECA PLC

FRA:ZEG (7/7/2025, 7:00:00 PM)

119.1

-1.2 (-1%)

Chartmill FA Rating
GICS SectorHealth Care
GICS IndustryGroupPharmaceuticals, Biotechnology & Life Sciences
GICS IndustryPharmaceuticals
Earnings (Last)04-29 2025-04-29/bmo
Earnings (Next)07-29 2025-07-29/bmo
Inst Owners46.88%
Inst Owner ChangeN/A
Ins Owners0.04%
Ins Owner ChangeN/A
Market Cap369.26B
Analysts82.86
Price Target158.42 (33.01%)
Short Float %N/A
Short RatioN/A
Dividend
Industry RankSector Rank
Dividend Yield 2.41%
Yearly Dividend2.54
Dividend Growth(5Y)1.4%
DP63.6%
Div Incr Years0
Div Non Decr Years0
Ex-DateN/A
Surprises & Revisions
EPS beat(2)1
Avg EPS beat(2)4.34%
Min EPS beat(2)-0.63%
Max EPS beat(2)9.32%
EPS beat(4)2
Avg EPS beat(4)1.86%
Min EPS beat(4)-1.9%
Max EPS beat(4)9.32%
EPS beat(8)5
Avg EPS beat(8)2.24%
EPS beat(12)9
Avg EPS beat(12)3.68%
EPS beat(16)11
Avg EPS beat(16)2.44%
Revenue beat(2)1
Avg Revenue beat(2)-0.64%
Min Revenue beat(2)-3.99%
Max Revenue beat(2)2.7%
Revenue beat(4)2
Avg Revenue beat(4)-0.21%
Min Revenue beat(4)-3.99%
Max Revenue beat(4)2.7%
Revenue beat(8)4
Avg Revenue beat(8)-0.19%
Revenue beat(12)4
Avg Revenue beat(12)-0.55%
Revenue beat(16)8
Avg Revenue beat(16)0.72%
PT rev (1m)-3.08%
PT rev (3m)-6.75%
EPS NQ rev (1m)-0.1%
EPS NQ rev (3m)-0.61%
EPS NY rev (1m)0%
EPS NY rev (3m)-0.16%
Revenue NQ rev (1m)-0.28%
Revenue NQ rev (3m)0.1%
Revenue NY rev (1m)0%
Revenue NY rev (3m)0.84%
Valuation
Industry RankSector Rank
PE 16.16
Fwd PE 13.34
P/S 7.88
P/FCF 47.39
P/OCF 33.09
P/B 10.55
P/tB N/A
EV/EBITDA 22.95
EPS(TTM)7.37
EY6.19%
EPS(NY)8.93
Fwd EY7.5%
FCF(TTM)2.51
FCFY2.11%
OCF(TTM)3.6
OCFY3.02%
SpS15.12
BVpS11.29
TBVpS-4.85
PEG (NY)1.29
PEG (5Y)0.87
Profitability
Industry RankSector Rank
ROA 7.31%
ROE 18.94%
ROCE 17.15%
ROIC 14.1%
ROICexc 15.14%
ROICexgc 76.66%
OM 24.05%
PM (TTM) 14.14%
GM 82.36%
FCFM 16.62%
ROA(3y)5.35%
ROA(5y)4.19%
ROE(3y)13.78%
ROE(5y)12.42%
ROIC(3y)11.62%
ROIC(5y)9.52%
ROICexc(3y)12.66%
ROICexc(5y)10.55%
ROICexgc(3y)112.76%
ROICexgc(5y)85.06%
ROCE(3y)13.95%
ROCE(5y)11.45%
ROICexcg growth 3Y43.28%
ROICexcg growth 5Y4.77%
ROICexc growth 3Y41%
ROICexc growth 5Y11.99%
OM growth 3Y21.43%
OM growth 5Y8.6%
PM growth 3Y251.6%
PM growth 5Y18.9%
GM growth 3Y3.31%
GM growth 5Y0.47%
F-Score9
Asset Turnover0.52
Health
Industry RankSector Rank
Debt/Equity 0.71
Debt/FCF 3.46
Debt/EBITDA 1.47
Cap/Depr 58.81%
Cap/Sales 7.18%
Interest Coverage 9.49
Cash Conversion 65.63%
Profit Quality 117.58%
Current Ratio 0.9
Quick Ratio 0.7
Altman-Z 4.95
F-Score9
WACC8.83%
ROIC/WACC1.6
Cap/Depr(3y)61.87%
Cap/Depr(5y)60.41%
Cap/Sales(3y)7.51%
Cap/Sales(5y)7.64%
Profit Quality(3y)144.6%
Profit Quality(5y)772.45%
High Growth Momentum
Growth
EPS 1Y (TTM)16.91%
EPS 3Y15.85%
EPS 5Y18.59%
EPS Q2Q%20.87%
EPS Next Y12.48%
EPS Next 2Y12.94%
EPS Next 3Y11.87%
EPS Next 5Y11.35%
Revenue 1Y (TTM)15.48%
Revenue growth 3Y13.06%
Revenue growth 5Y17.27%
Sales Q2Q%7.17%
Revenue Next Year8.37%
Revenue Next 2Y7.23%
Revenue Next 3Y6.74%
Revenue Next 5Y6.34%
EBIT growth 1Y42.22%
EBIT growth 3Y37.28%
EBIT growth 5Y27.35%
EBIT Next Year34.44%
EBIT Next 3Y17.32%
EBIT Next 5Y14.19%
FCF growth 1Y51.52%
FCF growth 3Y24.58%
FCF growth 5Y70.22%
OCF growth 1Y34.8%
OCF growth 3Y25.76%
OCF growth 5Y31.92%